Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
21,390,291
-
Shares change
-
+3,406,072
-
Total reported value, excl. options
-
$320,854,510
-
Value change
-
+$51,912,609
-
Put/Call ratio
-
75%
-
Number of buys
-
63
-
Number of sells
-
-30
-
Price
-
$15.00
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q4 2023
120 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q4 2023.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21,390,291 shares
of 46,239,275 outstanding shares and own 46% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (3,083,430 shares), GREAT POINT PARTNERS LLC (2,620,545 shares), MENORA MIVTACHIM HOLDINGS LTD. (2,303,031 shares), RTW INVESTMENTS, LP (1,726,808 shares), BlackRock Inc. (1,719,304 shares), CREDIT SUISSE AG/ (1,200,000 shares), Harel Insurance Investments & Financial Services Ltd. (870,045 shares), Migdal Insurance & Financial Holdings Ltd. (648,302 shares), SILVERARC CAPITAL MANAGEMENT, LLC (525,404 shares), and Wildcat Capital Management, LLC (495,606 shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.